TBScience 2020 Submission Guidelines

TBScience is now incorporated into the Union World Conference programme, which is being held virtually for the first time this year. This is the third annual TBScience, an official event entirely devoted to basic and translational tuberculosis (TB) research.

Held during the main conference between 20-24 October, the conference will be in a fully virtual format this year. The presenting author by submitting their abstract agrees to make themselves (or a colleague) available during the congress for a virtual question and answer session/ poster tour/ and or record a short presentation that can be placed online within the conference platform.

INFORMATION FOR AUTHORS

  • All TBScience 2020 abstracts must be submitted online via the dedicated system that will be available from 15 June to 29 July. Abstracts submitted by email or any alternative method will not be considered.
  • Persons submitting TBScience 2020 abstracts will be notified of acceptance or rejection of their submissions by 20 August 2020.
  • If you represent a UN organisation, please select the name of the organisation from the list available in the drop down menu.
  • A listed co-author other than the corresponding author may register and present the study at the conference. The corresponding author is responsible for the session content. S/he is the contact person for submission and communication purposes and is also responsible for disseminating information related to the session to the co-authors.
  • The maximum number of authors and institutions is eight.
  • When submitting, click on “Institutes” to provide details of your affiliation. If all authors belong to a single institution, you do not need to create new affiliations for each author.
  • Please note that alternate language interpretations of presentations will not be provided.

ABSTRACT INFORMATION

Abstracts should:

  • Address at least one of the four session themes (see below).
  • Contain original data, which has not been published at the time of the abstract submission deadline.
  • Focus on the following research fields:
    • Basic research (microbiology, immunology, -omics, etc)
    • Animal model studies
    • Clinical research
    • Epidemiology and transmission modeling

Please note: Abstracts will not be accepted if they relate to:

  • Implementation, operational and programmatic research
  • Descriptive epidemiology (e.g. prevalence surveys)
  • Health economics, social science research

THEMES

All abstracts must be submitted under one of these four session themes:

Theme 1: Role of innate and adaptive immunity in TB, and evaluation of immune correlates in preclinical and clinical studies

In this session recent insights into the host immune response to Mtb infection will be discussed. The results from a first TB biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.

Theme 2: Dead or alive? Implications of spectrum of M. tuberculosis infection

Recent research has suggested that M. tuberculosis can present as more subtle states than just “latent” infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modeling and economic analyses implications. This session is intended to discuss different implications of the spectrum of TB infection.

Theme 3: Resistance to new drugs

Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and ultimately undermines elimination strategies. For this reason, understanding the detailed mechanisms of resistance as well as interactions between the host and different drugs is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility notably based on genome sequence data.

Theme 4: Innovations in TB therapeutics

TB therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is much welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions, and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development, and genomic discoveries with relevance to development of host-directed therapies for curing TB.

TEXT

  • The abstract should be in English, and no more than 300 words.
  • Type the title of the abstract in upper and lower case, using capitals only for the first word, acronyms and proper nouns. Titles of more than 25 words (110 characters and spaces) will be truncated.
  • One table or one figure may be included with the abstract.
    • If you wish to submit a table with your abstract, note that it should be no larger than five rows by 10 columns.
    • If you wish to submit a figure with your abstract, note the maximum file size of each graph /image is 5 MB. The maximum pixel size of the graph is 600(w) x 800(h). You may upload graphs in JPG, GIF or PNG format.
    • Recommended resolution: mi 150 dpi, 300 dpi for images, 600 dpi for line art (charts).
    • Important: the graphic content must be clearly legible when previewing the abstract.
    • Low-resolution images will not be included in the Abstract Book.
    • Please note that tables and figures are reproduced in a single column with the abstract and that legibility is the responsibility of the author.
    • We recommend that you use a sans serif (Arial or Calibri) font for clarity.
  • Use the palette of characters provided to insert symbols, accents and special formatting (e.g., italics, bold, β, μ, etc.).
  • Abbreviations and acronyms must be written out in full at the first mention in the text.
  • Authors are responsible for proofreading and submitting an abstract without errors, as they will be reproduced in the form they were submitted.

ORGANISATION

  • Authors are given flexibility with regards to the structure of their abstract.
  • No imposed abstract sections such as Background, Methods, Results and Conclusions are required.
  • It is the responsibility of the author to present the abstract in a cohesive way.

USE OF NON-STIGMATISING LANGUAGE

SUBMISSION PROCESS

SUBMITTING AN ABSTRACT

  • To submit a new abstract, create a user account on the abstract submission platform.
  • Ensure that you carefully read all instructions given on the screen at each step of the process.
  • Do not upload the text of your abstract as an attachment. Abstracts submitted as attachments will not be considered.
  • Please refrain from submitting multiple abstracts on the same topic by varying the authors or under different titles with only minor word changes. In such cases, all of the submissions on that topic will be automatically rejected.

SUBMITTING A POST

The corresponding author will receive an email confirming that the submitted abstract has been received successfully, with an attachment of the submission.

After the abstract has been submitted, it can still be edited. However, please make sure that you submit it in its final version before the deadline.

REVIEW

All submitted abstracts will be sent for peer review by a panel of international experts. The scores will then be submitted to a reviewing committee. Note that decisions of the abstract review committee are final and cannot be appealed.

NOTIFICATION

  • Corresponding authors will be notified of acceptance of their late-breaker sessions by 20 August.
  • Abstracts that are not accepted cannot be reconsidered for review or presentation at the conference.

TO INCLUDE WITH APPLICATION

  • Confirmation that the work has not been previously submitted for consideration to the general portion of the Union World Conference.
  • The address, phone and email address where the author may be contacted.

 

If you have any questions, contact tbscience@theunion.org 

Back to top

Receive Conference News & Updates